Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar 5;3(3):e1725.
doi: 10.1371/journal.pone.0001725.

Overestimates of survival after HAART: implications for global scale-up efforts

Gregory P Bisson  1 , Tendani Gaolathe, Robert Gross, Caitlin Rollins, Scarlett Bellamy, Mpho Mogorosi, Ava Avalos, Harvey Friedman, Diana Dickinson, Ian Frank, Ndwapi Ndwapi
Affiliations

Overestimates of survival after HAART: implications for global scale-up efforts

Gregory P Bisson et al. PLoS One. .

Abstract

Background: Monitoring the effectiveness of global antiretroviral therapy scale-up efforts in resource-limited settings is a global health priority, but is complicated by high rates of losses to follow-up after treatment initiation. Determining definitive outcomes of these lost patients, and the effects of losses to follow-up on estimates of survival and risk factors for death after HAART, are key to monitoring the effectiveness of global HAART scale-up efforts.

Methodology/principal findings: A cohort study comparing clinical outcomes and risk factors for death after HAART initiation as reported before and after tracing of patients lost to follow-up was conducted in Botswana's National Antiretroviral Therapy Program. 410 HIV-infected adults consecutively presenting for HAART were evaluated. The main outcome measures were death or loss to follow-up within the first year after HAART initiation. Of 68 patients initially categorized as lost, over half (58.8%) were confirmed dead after tracing. Patient tracing resulted in reporting of significantly lower survival rates when death was used as the outcome and losses to follow-up were censored [1-year Kaplan Meier survival estimate 0.92 (95% confidence interval, 0.88-0.94 before tracing and 0.83 (95% confidence interval, 0.79-0.86) after tracing, log rank P<0.001]. In addition, a significantly increased risk of death after HAART among men [adjusted hazard ratio 1.74 (95% confidence interval, 1.05-2.87)] would have been missed had patients not been traced [adjusted hazard ratio 1.41 (95% confidence interval, 0.65-3.05)].

Conclusions/significance: Due to high rates of death among patients lost to follow-up after HAART, survival rates may be inaccurate and important risk factors for death may be missed if patients are not actively traced. Patient tracing and uniform reporting of outcomes after HAART are needed to enable accurate monitoring of global HAART scale-up efforts.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Kaplan-Meier curve 52-week survival estimates before and after patient tracing, IDCC, Gaborone, Botswana.
Losses to follow-up are censored. Log rank P <0.001.
See this image and copyright information in PMC

References

    1. UNAIDS. 2006. 2006 Report on the global AIDS epidemic. A UNAIDS 10th anniversary special edition. Executive summary.: Joint United Nations Programme on HIV/AIDS.
    1. WHO. Geneva: WHO; 2006. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2006 Revision.
    1. Rosen S, Fox MP, Gill CJ. Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Med. 2007;4:e298. - PMC - PubMed
    1. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids. 2004;18:887–895. - PubMed
    1. Guiard-Schmid JBMB, Ribadeau-Dumas F, Edoo G, Makong S, Bidjeck M, Marechal E, Nerrienet E, Chevallier-Schwartz M, Buclez B, Longuet C, Le Pen C, Pialous G, Rozenbaum W. TRICAM: Medico-economic pilot study on HAART for HIV-infected patients in a private company of Cameroon [abstract]. 2004 July 11-16; Bangkok, Thailand

Publication types

Substances